What drives impactful communications in life sciences? David Schull, President of Russo Partners, joins Jeff Harmon on the Conversations Life Science Leaders Aren’t Having podcast to discuss the power of storytelling and how to foster innovation in healthcare. From navigating complex communications to supporting transformative science, this episode is packed with insights for biotech leaders. Watch on YouTube: https://bit.ly/40lucuO Listed on Apple Podcasts: https://apple.co/40lud1Q #LifeSciences #Leadership #HealthcareInnovation
Russo Partners
Public Relations and Communications Services
New York, NY 1,273 followers
Public and investor relations for the innovators in healthcare and technology.
About us
Since our founding in 1988, Russo Partners has been working side by side with innovators and influencers in the healthcare and technology industries. Our evolution in the biopharma and healthcare technology ecosystem is unparalleled as is our network, and the knowledge we bring to our clients is extensive. We bring passion, a culture of excellence, forward thinking and client focus every day to everything we do.
- Website
-
http://www.russopartnersllc.com
External link for Russo Partners
- Industry
- Public Relations and Communications Services
- Company size
- 11-50 employees
- Headquarters
- New York, NY
- Type
- Privately Held
- Founded
- 1988
- Specialties
- Media Relations, Messaging and Positioning, Investor Relations, Issue and Crisis Management, Clinical Trial Recruitment, Corporate Communications, Online Communications, Regulatory Communications, Professional and Advocacy Relations, and Sports-Health Alliance Offering
Locations
-
Primary
12 W 27th Street
4th Floor
New York, NY 10001, US
Employees at Russo Partners
-
Devin A. Brown
Digital Comms in Life Sciences | VP @ Russo Partners | Social & Digital Leader | Growth Marketer | 14-Year McKinsey Alum
-
Tony Russo, Ph.D.
Russo Partners
-
Scott Stachowiak
Health | Pharma | Biotech Communications | Media Relations Expertise and Counsel
-
David Schull
President, Russo Partners, LLC
Updates
-
🎧 In this latest episode of the Russo Edge Podcast, Kevin Caldwell, CEO, Co-founder, and President of Ossium Health, speaks with host solomon wilcots of Russo Partners about the first patient who received a transplant through the company’s organ transplant system. The patient underwent a bone marrow transplant, had full engraftment, and is now living a normal life again. This episode captures how the science, system, and vision in the healthcare field can impact individual patients’ lives and allow for a full recovery. To listen to the episode, visit: https://bit.ly/4iho1PD Apple Podcasts: https://apple.co/41qddbJ Watch on YouTube: https://bit.ly/3ZPbM5x #Biotech #Biopharma #BoneMarrow #Translplants
-
As the year ends, the team at Russo Partners extends our warmest holiday wishes to you and yours. The Union Square Climate Clock reminds us we have just 4 years and 214 days to make meaningful changes to prevent irreversible climate change. We're honored to support the Founder's Pledge Climate Change Fund, which provides crucial relief to those affected by natural and climate change-related disasters. Thank you for being part of our journey. Here's to a joyful holiday season and a hopeful New Year! #HolidayWishes
-
The growing excitement for radiopharmaceuticals this year continued last month with Ratio Therapeutics’ recent licensing agreement with Novartis. For more, visit Endpoints News: https://lnkd.in/d-vRK_vK Fierce Biotech: https://lnkd.in/eKRrN2nc #Radiopharma #Deals
-
In the newest episode of Conversations that Matter, David Bearss Ph.D., CEO of Halia Therapeutics, Inc., discusses the company’s goals for the first half of 2025, including the progression of two clinical-stage assets, the expansion of its pipeline, and its message to investors in 2025. Halia Therapeutics is discovering and developing novel therapies to improve patients' lives with inflammatory and neurological diseases. To learn more, please visit: https://haliatx.com/
-
🎧 On the latest episode of the Russo Edge Podcast, host solomon wilcots of Russo Partners interviews Kevin Caldwell, CEO, Co-founder and President of Ossium Health, who covers some of the hurdles faced by companies with innovative healthcare solutions. Kevin speaks about bridging the divide from bench to bedside and bringing things from a small scale at the early stage to high production levels and out into the world. Barriers and obstacles encountered, such as finding organ donors and building facilities capable of high production, are things encountered by entrepreneurs that can be overcome with grit and time. To listen to the episode, visit: https://bit.ly/4iho1PD Apple Podcasts: https://apple.co/41qddbJ Watch on YouTube: https://bit.ly/3ZPbM5x #Biotech #Biopharma #BoneMarrow #Translplants
-
A report from AsianInvestor highlights a growing interest in biotech investments across Asia, driven by family offices and institutional investors. With hubs like Hong Kong raising $35 billion through healthcare and biotech IPOs in 2023, the region shows signs of a sector revival as funding activity increases and interest rates ease. Read the full article: https://bit.ly/3Dc2d7N #BiotechInvestment #HealthcareInnovation
-
🎧 On the latest episode of the Russo Edge Podcast, host solomon wilcots of Russo Partners interviews Kevin Caldwell, CEO, Co-founder, and President of Ossium Health, covering his company’s groundbreaking approach to cancer transplants. In this episode, Kevin explains how Ossium Health is the first company to successfully take bone marrow tissue from deceased donors at scale and store the tissue until required. This type of transplant protocol will allow for more transplants for future patients. To listen to the episode, visit: https://lnkd.in/eczDST8X Apple Podcasts: https://lnkd.in/eCJ3N55W Watch on YouTube: https://lnkd.in/evxWXMrx #Biotech #Biopharma #BoneMarrow #Translplants
-
Per reporting by Fierce Biotech, biopharma venture funding surged in Q3 2024, reaching $7.2B across 187 deals, driven by large VCs and high-value megarounds. Exit activity also grew significantly, with $9.7B in deals, including notable IPOs and M&A moves. Learn more here: https://bit.ly/4iiQpk9 #Biopharma #VentureCapital #MergersAndAcquisitions
-
Russo Partners reposted this
Bruce Japsen leading the way with Annie Lamont and Jim Rechtin at the Forbes Healthcare Summit; Tony Russo, Ph.D. and I have worked with Bruce for several decades.